劲敌来了！罗氏口服减肥药早期试验结果乐观，诺和诺德和礼来股价齐跌

华尔街见闻07-17

减肥药“双雄”格局生变？周三，瑞士制药巨头罗氏宣布，其收购公司Carmot Therapeutics的第二种减肥药候选药物在早期试验中显示出积极效果，声明发布后，罗氏股价大涨超5%，后涨幅扩大至6%。据介绍，罗氏这款实验药CT-996是一款需每日口服一次的小分子GLP-1受体激动剂类药物。声明称，该药物在一项I期试验中，能够使患II型糖尿病的肥胖症患者的平均体重在四周内减少6.1%。罗氏...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2452592411?lang=zh_CN&edition=full","thumbnail":"https://wpimg-wscn.awtmt.com/e956a03b-5d62-434b-8743-3d6009dcd314.png","is_english":false,"pubTime":"2024-07-17 20:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2452592411","market":"us","top_or_hot":-1,"title":"劲敌来了！罗氏口服减肥药早期试验结果乐观，诺和诺德和礼来股价齐跌","media":"华尔街见闻","content":"<div>\n<p>减肥药“双雄”格局生变？\n周三，瑞士制药巨头罗氏宣布，其收购公司Carmot Therapeutics的第二种减肥药候选药物在早期试验中显示出积极效果，声明发布后，罗氏股价大涨超5%，后涨幅扩大至6%。\n\n据介绍，罗氏这款实验药CT-996是一款需每日口服一次的小分子GLP-1受体激动剂类药物。声明称，该药物在一项I期试验中，能够使患II型糖尿病的肥胖症患者的平均体重在四周内减少6.1%。\n罗氏...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3719915\">网页链接</a>\n\n</div>\n","source":"wallstreetcn_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>劲敌来了！罗氏口服减肥药早期试验结果乐观，诺和诺德和礼来股价齐跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n劲敌来了！罗氏口服减肥药早期试验结果乐观，诺和诺德和礼来股价齐跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-17 20:57 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3719915><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>减肥药“双雄”格局生变？\n周三，瑞士制药巨头罗氏宣布，其收购公司Carmot Therapeutics的第二种减肥药候选药物在早期试验中显示出积极效果，声明发布后，罗氏股价大涨超5%，后涨幅扩大至6%。\n\n据介绍，罗氏这款实验药CT-996是一款需每日口服一次的小分子GLP-1受体激动剂类药物。声明称，该药物在一项I期试验中，能够使患II型糖尿病的肥胖症患者的平均体重在四周内减少6.1%。\n罗氏...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3719915\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1623119135.USD","symbol_name":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","start_time":0,"source_url":"https://wallstreetcn.com/articles/3719915","article_id":"2452592411","we_media_id":null,"thumbnails":["https://wpimg-wscn.awtmt.com/e956a03b-5d62-434b-8743-3d6009dcd314.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3719915","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2452592411","pubTimestamp":1721221043,"sourceInfo":{"source_id":"wallstreetcn_hot_news","name":"华尔街见闻"},"weMediaInfo":null,"summary":"罗氏称，其实验性口服减肥药CT-996在一项I期试验中，能够使患II型糖尿病的肥胖症患者的平均体重在四周内减少6.1%。","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","NVO":"诺和诺德","MRNA":"Moderna, Inc.","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4516":"特朗普概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4532":"文艺复兴科技持仓","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4007":"制药","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"Here comes the enemy! Novo Nordisk and Eli Lilly shares fall after early trial results of Roche's oral weight loss pill are optimistic","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":0.8,"MRNA":0.6},"content_text":"减肥药“双雄”格局生变？\n周三，瑞士制药巨头罗氏宣布，其收购公司Carmot Therapeutics的第二种减肥药候选药物在早期试验中显示出积极效果，声明发布后，罗氏股价大涨超5%，后涨幅扩大至6%。\n\n据介绍，罗氏这款实验药CT-996是一款需每日口服一次的小分子GLP-1受体激动剂类药物。声明称，该药物在一项I期试验中，能够使患II型糖尿病的肥胖症患者的平均体重在四周内减少6.1%。\n罗氏首席医疗官Levi Garraway在声明中表示：\n\n“我们对CT-996口服GLP-1疗法在临床试验中显示出的显著体重减轻效果感到欣慰，这最终可能帮助患者解决长期体重管理和血糖控制的问题。”\n\n而减肥“双雄”诺和诺德和礼来的股价分别下跌3.77%和2.7%，二者分别生产Wegovy和Zepbound，是当前市场最为热销的两款GLP-1受体激动剂类药物，也被称作“减肥神药”。\n\n此外，正在开发自身肥胖治疗药物的丹麦生物技术公司Zealand Pharma的股价也下跌逾5%。\n\n与需要注射的“减肥神药”相比，罗氏这款减肥候选药物仅需每日口服，用药方式更为便捷。有分析称，这将为不喜欢注射药物的肥胖症患者提供替代品。\n不过，罗氏首席执行官Teresa Graham在去年12月接受采访时表示，口服肥胖治疗药物可能需要几年时间才能广泛上市。风险提示及免责条款\n\n            市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452592411"}